Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 5
2009 6
2010 6
2011 3
2012 4
2013 1
2014 6
2015 8
2016 11
2017 10
2018 18
2019 19
2020 26
2021 19
2022 28
2023 35
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Blauvelt A, et al. Among authors: eyerich k. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. JAMA Dermatol. 2021. PMID: 34347860 Free PMC article. Clinical Trial.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U. Reich K, et al. Among authors: eyerich k. Lancet. 2022 Jul 23;400(10348):273-282. doi: 10.1016/S0140-6736(22)01199-0. Lancet. 2022. PMID: 35871814 Clinical Trial.
Hidradenitis Suppurativa: Where We Are and Where We Are Going.
Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, Marasca C, Seiringer P, Volz T, Eyerich K, Fabbrocini G. Scala E, et al. Among authors: eyerich k. Cells. 2021 Aug 15;10(8):2094. doi: 10.3390/cells10082094. Cells. 2021. PMID: 34440863 Free PMC article. Review.
Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.
Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, Jakob T, Kapp A, Kolkhir P, Larenas-Linnemann D, Park HS, Pejler G, Sánchez-Borges M, Schäkel K, Simon D, Simon HU, Weller K, Zuberbier T, Metz M. Maurer M, et al. Among authors: eyerich k. Int Arch Allergy Immunol. 2020;181(5):321-333. doi: 10.1159/000507218. Epub 2020 Mar 30. Int Arch Allergy Immunol. 2020. PMID: 32224621 Free PMC article. Review.
European consensus statement on phenotypes of pustular psoriasis.
Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, Kingo K, Smith C, Barker JN; ERASPEN Network. Navarini AA, et al. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1792-1799. doi: 10.1111/jdv.14386. Epub 2017 Aug 29. J Eur Acad Dermatol Venereol. 2017. PMID: 28585342 Review.
Biomarkers of disease progression in people with psoriasis: a scoping review.
Ramessur R, Corbett M, Marshall D, Acencio ML, Barbosa IA, Dand N, Di Meglio P, Haddad S, Jensen AHM, Koopmann W, Mahil SK, Ostaszewski M, Rahmatulla S, Rastrick J, Saklatvala J, Weidinger S, Wright K, Eyerich K, Ndlovu M, Barker JN, Skov L, Conrad C, Smith CH; BIOMAP consortium. Ramessur R, et al. Among authors: eyerich k. Br J Dermatol. 2022 Oct;187(4):481-493. doi: 10.1111/bjd.21627. Epub 2022 Jul 11. Br J Dermatol. 2022. PMID: 35482474 Free PMC article. Review.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S, Hu X, Wu T, Calimlim BM, Kaplan B, Liu Y, Teixeira HD, Liu J, Eyerich K. Blauvelt A, et al. Among authors: eyerich k. J Am Acad Dermatol. 2023 Sep;89(3):478-485. doi: 10.1016/j.jaad.2023.05.033. Epub 2023 May 23. J Am Acad Dermatol. 2023. PMID: 37230366 Free article. Clinical Trial.
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
Lavazais S, Jargosch M, Dupont S, Labéguère F, Menet C, Jagerschmidt C, Ohm F, Kupcsik L, Parent I, Cottereaux C, Marsais F, Oste L, Van de Water A, Christophe T, De Vos S, Fallon P, Lauffer F, Clément-Lacroix P, Eyerich K, Brys R. Lavazais S, et al. Among authors: eyerich k. Sci Transl Med. 2023 Feb 15;15(683):eabj3289. doi: 10.1126/scitranslmed.abj3289. Epub 2023 Feb 15. Sci Transl Med. 2023. PMID: 36791209
Zytokine der IL-17-Familie bei der Psoriasis.
Lauffer F, Eyerich K, Boehncke WH, Asadullah K, Beissert S, Ghoreschi K, Schön MP. Lauffer F, et al. Among authors: eyerich k. J Dtsch Dermatol Ges. 2020 Jul;18(7):675-681. doi: 10.1111/ddg.14124_g. J Dtsch Dermatol Ges. 2020. PMID: 32713148 Review. German.
COVID‐19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen.
Schön MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Schäkel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K. Schön MP, et al. Among authors: eyerich k. J Dtsch Dermatol Ges. 2020 Aug;18(8):795-809. doi: 10.1111/ddg.14169_g. J Dtsch Dermatol Ges. 2020. PMID: 32881300 Free PMC article. Review. German.
180 results